Proclara Biosciences Australia awarded grant to help develop new biotherapy with blockbuster potential
Work on a second-generation fusion protein due to start in 2017 at Patheon's manufacturing facility in Brisbane.
Proclara Biosciences has been awarded a grant of $250,000 to support the development of NPT189 for the treatment of Alzheimer’s and other age-related neurological diseases. NPT189 is a second-generation fusion protein manufactured using advanced cell culture methods. The work is projected to start in 2017 at Patheon’s state-of-the-art manufacturing facility in Brisbane. The material produced from the scale-up batch will be used in preclinical studies required for regulatory approvals and to de-risk the transition to large scale cGMP manufacture.
Proclara Biosciences has also been awarded an establishment grant of $25,000 from Biopharmaceuticals Australia (BPA). The establishment of Proclara Biosciences Australia paves the way for the company to develop its unique biodrugs using Australia’s globally competitive service providers.
Proclara’s drug candidates simultaneously target the multiple misfolded proteins implicated in neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and other age-related degenerative diseases of the central nervous system. Proclara’s drug candidates may also be used to treat other protein-misfolding diseases, including systemic amyloidosis.
BPA’s Biopharmaceutical Development Fund of more than $2 million has pioneered support in Australia for new medicines in pre-clinical and early clinical development. BPA has already committed $1.8M to support biotech companies in developing biodrugs in association with Patheon. BPA estimates that its Patheon partnership returned a total economic benefit to Australia of over $100 million in under 3 years, with over $1 billion return forecast over 10 years.
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
.png)
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.